Latest News
21.02.2012
Antitope announces the launch of new Composite CHO technology for development of manufacturing cell lines suitable for biologics
Antitope today announced the launch of Composite CHO technology for the generation of CHO cell lines suitable for cGMP manufacture of recombinant antibodies and proteins. The Composite CHO technology has been developed for direct transfer of genes into CHO cells pre-adapted to grow in...
Antitope announces the launch of new Composite CHO technology for development of manufacturing cell lines suitable for biologics
Antitope today announced the launch of Composite CHO technology for the generation of CHO cell lines suitable for cGMP manufacture of recombinant antibodies and proteins. The Composite CHO technology has been developed for direct transfer of genes into CHO cells pre-adapted to grow in...
07.11.2011
Antitope, Ltd., Announces Antibody Research Agreement with Therapure Biopharma, Inc.
Cambridge UK, 7th November 2011- Antitope Ltd., UK ("Antitope") today announced a research agreement with Therapure Biopharma Inc., Canada ("Therapure") for the generation of therapeutic monoclonal antibodies. Under the Agreement, Antitope will apply its proprietary Composite...
Antitope, Ltd., Announces Antibody Research Agreement with Therapure Biopharma, Inc.
Cambridge UK, 7th November 2011- Antitope Ltd., UK ("Antitope") today announced a research agreement with Therapure Biopharma Inc., Canada ("Therapure") for the generation of therapeutic monoclonal antibodies. Under the Agreement, Antitope will apply its proprietary Composite...
31.10.2011
Antitope Announces Initiation of Antibody Humanization in Collaboration with Kolltan Pharmaceuticals
Cambridge UK, 31st October 2011 - Antitope Ltd., UK ("Antitope") today announced a research agreement with Kolltan Pharmaceuticals, Inc. ("Kolltan") for the generation of therapeutic monoclonal antibodies for the treatment of cancer. Under the agreement, Antitope will apply its...
Antitope Announces Initiation of Antibody Humanization in Collaboration with Kolltan Pharmaceuticals
Cambridge UK, 31st October 2011 - Antitope Ltd., UK ("Antitope") today announced a research agreement with Kolltan Pharmaceuticals, Inc. ("Kolltan") for the generation of therapeutic monoclonal antibodies for the treatment of cancer. Under the agreement, Antitope will apply its...
19.10.2011
EUROCALIN Consortium Initiates EU Grant Funded Collaboration to Develop Novel Anticalin Therapeutic to Treat Anemia
--Consortium Will Receive Six Million Euros from Seventh Framework Programme-- Freising, Germany, October 19th, 2011—The EUROCALIN Consortium, comprising 10 companies and universities from across Europe, has initiated a collaboration focused on attaining and completing initial clinical...
EUROCALIN Consortium Initiates EU Grant Funded Collaboration to Develop Novel Anticalin Therapeutic to Treat Anemia
--Consortium Will Receive Six Million Euros from Seventh Framework Programme-- Freising, Germany, October 19th, 2011—The EUROCALIN Consortium, comprising 10 companies and universities from across Europe, has initiated a collaboration focused on attaining and completing initial clinical...
27.07.2011
Antitope Ltd. Announces Research Cooperation with the University of North Carolina at Chapel Hill
Cambridge UK, 27th July 2011 - Antitope Ltd., Cambridge UK (“Antitope”) today announced a research collaboration with the University of North Carolina at Chapel Hill, NC, USA (“UNC”) for the generation of monoclonal therapeutic antibodies for the treatment of cancer. During...
Antitope Ltd. Announces Research Cooperation with the University of North Carolina at Chapel Hill
Cambridge UK, 27th July 2011 - Antitope Ltd., Cambridge UK (“Antitope”) today announced a research collaboration with the University of North Carolina at Chapel Hill, NC, USA (“UNC”) for the generation of monoclonal therapeutic antibodies for the treatment of cancer. During...
14.06.2011
Antitope Announces Humanization Research Agreement with IMMIH, University of Cologne
Cambridge UK, 14th June 2011 - Antitope Ltd., Cambridge UK (“Antitope”) today announced a research agreement with the Institute for Medical Microbiology, Immunology and Hygiene, University of Cologne, Germany (“IMMIH“) for the generation of monoclonal therapeutic antibodies...
Antitope Announces Humanization Research Agreement with IMMIH, University of Cologne
Cambridge UK, 14th June 2011 - Antitope Ltd., Cambridge UK (“Antitope”) today announced a research agreement with the Institute for Medical Microbiology, Immunology and Hygiene, University of Cologne, Germany (“IMMIH“) for the generation of monoclonal therapeutic antibodies...
06.06.2011
Antitope Announces Humanization Research Agreement with NasVax
Cambridge UK, 7th June 2011 - Antitope Ltd., Cambridge UK (“Antitope”) today announced a research collaboration with NasVax Ltd., Israel (“NasVax“) for the generation of monoclonal therapeutic antibodies for the treatment of inflammatory and autoimmune diseases. During the...
Antitope Announces Humanization Research Agreement with NasVax
Cambridge UK, 7th June 2011 - Antitope Ltd., Cambridge UK (“Antitope”) today announced a research collaboration with NasVax Ltd., Israel (“NasVax“) for the generation of monoclonal therapeutic antibodies for the treatment of inflammatory and autoimmune diseases. During the...
25.05.2011
Meet Antitope at BIO International Convention 2011 (Washington DC, USA, 27th – 30th June)
Antitope will be participating in the Business Partnering Forum at the BIO International Convention and welcome the opportunity to discuss potential collaborations with companies that are interested in the assessment and removal of immunogenicity from protein therapeutics. Meetings can be arranged...
Meet Antitope at BIO International Convention 2011 (Washington DC, USA, 27th – 30th June)
Antitope will be participating in the Business Partnering Forum at the BIO International Convention and welcome the opportunity to discuss potential collaborations with companies that are interested in the assessment and removal of immunogenicity from protein therapeutics. Meetings can be arranged...
13.04.2011
Cellmid Signs Antibody Humanisation Collaboration with Antitope
SYDNEY, 13 April 2011: Cellmid Limited (ASX: CDY) has signed a collaboration agreement with Antitope Ltd (Cambridge, UK) for the humanisation of its lead therapeutic monoclonal antibody candidate. The collaboration is expected to deliver a drug candidate, a first in class humanised anti-midkine...
Cellmid Signs Antibody Humanisation Collaboration with Antitope
SYDNEY, 13 April 2011: Cellmid Limited (ASX: CDY) has signed a collaboration agreement with Antitope Ltd (Cambridge, UK) for the humanisation of its lead therapeutic monoclonal antibody candidate. The collaboration is expected to deliver a drug candidate, a first in class humanised anti-midkine...